Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 2×
“The threshold of the ORR (under the null hypothesis) was set as 10 %, and the expected ORR (under the alternative hypothesis) was set at 30 % based on results of previous studies [5, 6, 11].”
MethodIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 2×
“In two recent studies using gemcitabine monotherapy as control arm, MPACT and FOLFIRINOX study, improved OS was observed in nab-paclitaxel plus gemcitabine (gemcitabine-based regimen) and FOLFIRINOX (gemcitabine-free regimen) compared to gemcitabine monotherapy, thereby broadening the first-line treatment options [6,…”
MethodBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“In phase III trials, nab-paclitaxel significantly increased time to progression and overall response rate (ORR) compared with conventional paclitaxel in patients with metastatic breast cancer [8], and significantly improved ORR in advanced nonsmall cell lung cancer patients [9].”
BackgroundDesai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175 · cited 1×
“Preclinical studies suggested that nab-paclitaxel takes advantage of endogenous albumin transport pathways to deliver higher doses of paclitaxel to the tumor [7].”
BackgroundVon Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044 · cited 2×
“Nab-paclitaxel monotherapy and in combination with gemcitabine showed antitumor activity against advanced PC [10, 11].”
BackgroundPancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W., Benson, A. B., Binder, E., Cardin, D. B., Cha, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0131 · Cited by 1,020
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“In phase III trials, nab-paclitaxel significantly increased time to progression and overall response rate (ORR) compared with conventional paclitaxel in patients with metastatic breast cancer [8], and significantly improved ORR in advanced nonsmall cell lung cancer patients [9].”
Background
Metadata
- Authors
- Ueno, H., Ikeda, M., Ueno, M., Mizuno, N., Ioka, T., Omuro, Y., Nakajima, T. E., & Furuse, J.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2016-02-03
- Volume
- 77
- Issue
- 3
- Pages
- 595-603
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2267156748
- Cited by
- 158
- References
- 23
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. https://app.cochat.ai/papers/10.1007/s00280-016-2972-3
- The paper
- Ueno, H., Ikeda, M., Ueno, M., Mizuno, N., Ioka, T., Omuro, Y., Nakajima, T. E., & Furuse, J. (2016). Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-016-2972-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.